jacobio pharmaceuticals group co ltd - JBPHF

JBPHF

Close Chg Chg %
0.30 0.57 193.75%

Open Market

0.87

+0.57 (193.75%)

Volume: 2.43K

Last Updated:

Aug 25, 2025, 11:37 AM EDT

Company Overview: jacobio pharmaceuticals group co ltd - JBPHF

JBPHF Key Data

Open

$0.87

Day Range

0.87 - 0.87

52 Week Range

0.87 - 0.87

Market Cap

$686.27M

Shares Outstanding

788.82M

Public Float

417.45M

Beta

-245.01

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

N/A

 

JBPHF Performance

No Data Available

JBPHF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About jacobio pharmaceuticals group co ltd - JBPHF

Jacobio Pharmaceuticals Group Co., Ltd. is an investment holding company, which engages in the research and development of pharmaceutical products. The company was founded on June 01, 2018 and is headquartered in Beijing, China.

JBPHF At a Glance

Jacobio Pharmaceuticals Group Co., Ltd.
Building 8
Beijing, Beijing 101111
Phone 86-10-56315466 Revenue 21.64M
Industry Biotechnology Net Income -21,635,813.13
Sector Health Technology 2024 Sales Growth 141.325%
Fiscal Year-end 12 / 2025 Employees 257
View SEC Filings

JBPHF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 5.855
Price to Book Ratio 1.02
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.043
Enterprise Value to Sales 0.053
Total Debt to Enterprise Value 30.705

JBPHF Efficiency

Revenue/Employee 84,185.503
Income Per Employee -84,186.043
Receivables Turnover 15.507
Total Asset Turnover 0.11

JBPHF Liquidity

Current Ratio 4.895
Quick Ratio 4.895
Cash Ratio 4.837

JBPHF Profitability

Gross Margin 83.008
Operating Margin -139.697
Pretax Margin -100.001
Net Margin -100.001
Return on Assets -11.035
Return on Equity -15.575
Return on Total Capital -13.367
Return on Invested Capital -13.126

JBPHF Capital Structure

Total Debt to Total Equity 27.981
Total Debt to Total Capital 21.864
Total Debt to Total Assets 19.006
Long-Term Debt to Equity 20.837
Long-Term Debt to Total Capital 16.281
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Jacobio Pharmaceuticals Group Co Ltd - JBPHF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
23.69M 14.22M 8.97M 21.64M
Sales Growth
-66.37% -39.99% -36.95% +141.32%
Cost of Goods Sold (COGS) incl D&A
23.05M 14.21M 11.95M 3.68M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.67M 2.05M 3.54M 3.68M
Depreciation
1.60M 1.94M 3.47M 3.60M
Amortization of Intangibles
73.65K 110.79K 68.31K 72.81K
COGS Growth
+206.89% -38.35% -15.91% -69.23%
Gross Income
641.30K 8.02K (2.98M) 17.96M
Gross Income Growth
-98.98% -98.75% -37,308.73% +701.87%
Gross Profit Margin
+2.71% +0.06% -33.28% +83.01%
2021 2022 2023 2024 5-year trend
SG&A Expense
49.11M 70.63M 55.69M 48.18M
Research & Development
42.30M 64.51M 49.55M 42.84M
Other SG&A
6.81M 6.12M 6.15M 5.35M
SGA Growth
+65.00% +43.83% -21.15% -13.48%
Other Operating Expense
- - - -
-
Unusual Expense
(1.47M) 448.79K 1.55M (411.02K)
EBIT after Unusual Expense
(47.00M) (71.07M) (60.23M) (29.81M)
Non Operating Income/Expense
387.48K 16.19M 10.71M 9.34M
Non-Operating Interest Income
2.91M 3.65M 6.64M 5.68M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
88.07K 337.11K 1.17M 1.17M
Interest Expense Growth
-59.39% +282.77% +248.01% -0.52%
Gross Interest Expense
88.07K 337.11K 1.17M 1.17M
Interest Capitalized
- - - -
-
Pretax Income
(46.70M) (55.22M) (50.69M) (21.64M)
Pretax Income Growth
+78.71% -18.25% +8.22% +57.31%
Pretax Margin
-197.10% -388.38% -565.36% -100.00%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(46.70M) (55.22M) (50.69M) (21.64M)
Minority Interest Expense
- - - -
-
Net Income
(46.70M) (55.22M) (50.69M) (21.64M)
Net Income Growth
+78.70% -18.25% +8.22% +57.31%
Net Margin Growth
-197.10% -388.38% -565.36% -100.00%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(46.70M) (55.22M) (50.69M) (21.64M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(46.70M) (55.22M) (50.69M) (21.64M)
EPS (Basic)
-0.0625 -0.0734 -0.0656 -0.0279
EPS (Basic) Growth
+78.02% -17.44% +10.63% +57.47%
Basic Shares Outstanding
747.29M 751.88M 772.84M 774.81M
EPS (Diluted)
-0.0625 -0.0734 -0.0656 -0.0279
EPS (Diluted) Growth
+78.02% -17.44% +10.63% +57.47%
Diluted Shares Outstanding
747.29M 751.88M 772.84M 774.81M
EBITDA
(46.79M) (68.58M) (55.14M) (26.55M)
EBITDA Growth
-236.05% -46.55% +19.60% +51.85%
EBITDA Margin
-197.50% -482.29% -615.01% -122.71%

Jacobio Pharmaceuticals Group Co Ltd in the News